FDA cleared the device for use in adults with type 2 diabetes in ... of adults achieving an HbA1c of less than 7% rose from 14% at baseline to 37% at 13 weeks. Time in range rose from 45% at ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

Hybrid closed-loop insulin delivery does not affect rate of severe hypoglycemia and increases rate of ketoacidosis.

Researchers at the University of Exeter have devised an innovation that gives hope for the future, as a new study reveals ...

The glucose surge can also be inhibited ... Thiazolidinediones (TZDs) achieve HbA1c reductions in the 0.5–1.5% range in monotherapy by activation of the peroxisome proliferator-activated ...

In this randomized controlled trial, insulin alfa efsitora (efsitora) demonstrated noninferiority to degludec in reducing ...

A nonrandomized clinical trial found that HbA1c levels decreased in a diverse group of adults with type 2 diabetes after ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies*, insulin administration is manually controlled, while hybrid ...

Millions of people with type 2 diabetes could receive better treatment thanks to a new, simple low-cost tool, according to groundbreaking research announced today at the Diabetes UK Professional ...

The doctor called her back a few days later with the results from her HbA1C, which measures the amount of glucose in the blood - a red flag for diabetes. The health range is under 40 mmol/mol.